CVE:LXG

LexaGene Stock Forecast, Price & News

C$0.75
-0.01 (-1.32 %)
(As of 04/9/2021 03:59 PM ET)
Add
Compare
Today's Range
C$0.74
Now: C$0.75▼
C$0.77
50-Day Range
C$0.76
MA: C$1.02▼
C$1.24
52-Week Range
C$0.50
Now: C$0.75▼
C$1.54
Volume135,639 shs
Average Volume477,538 shs
Market CapitalizationC$85.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated genetic analyzers for pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company is headquartered in Beverly, Massachusetts.

Industry, Sector and Symbol

Stock Exchange CVE
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolCVE:LXG
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.lexagene.com
Phone800-215-1824
Employees36
Year FoundedN/A

Debt

Debt-to-Equity Ratio16.27
Current Ratio19.13
Quick Ratio17.50

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowC$0.08 per share
Price / Cash Flow9.88
Book ValueC$0.09 per share
Price / Book8.24

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares114,362,000
Market CapC$85.77 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Reports Update in Shareholder Letter - StreetInsider.com
April 2, 2021 |  streetinsider.com
NA Proactive news snapshot: Vuzix, Cardiol Therapeutics, AgraFlora Organics, ImagineAR, LexaGene, Cloud Nine Web3 UPDATE... - Proactive Investors USA & Canada
April 1, 2021 |  proactiveinvestors.com
LexaGene Holdings ramps up manufacturing of its flagship MiQLab system - Proactive Investors USA
April 1, 2021 |  proactiveinvestors.com
LexaGene's Provides Corporate Update TSX Venture Exchange:LXG - GlobeNewswire - GlobeNewswire
April 1, 2021 |  globenewswire.com
Highlights From Day 2 Of Benzinga's Biotech Small Cap Conference - Benzinga
March 26, 2021 |  benzinga.com
LexaGene advances its pathogen-detection technology in battle against coronavirus
March 3, 2021 |  proactiveinvestors.com
LexaGene says it has received approximately C$3.6M (US$2.9M) in warrant exercises since the start of 2021 - Proactive Investors USA & Canada
March 2, 2021 |  proactiveinvestors.com
BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Secures $3.6M from Exercised Warrants - StreetInsider.com
March 2, 2021 |  streetinsider.com
LexaGene Receives $3.6M from the Exercise of Warrants - GlobeNewswire
March 2, 2021 |  globenewswire.com
LexaGene Holdings says its president Daryl Rebeck will resign from his position and the board
February 12, 2021 |  proactiveinvestors.com
Wall Street slides at the opening bell
February 12, 2021 |  proactiveinvestors.com
Lexagene’s MiQLab takes another step forward successfully detecting UK and South African Variants
February 10, 2021 |  proactiveinvestors.com
LexaGene successfully configures its MiQLab system to detect mutant sequences unique to UK and South African coronavirus variants
February 10, 2021 |  proactiveinvestors.com
LexaGene Holdings initiates program to identify the UK and South African variants of coronavirus
January 14, 2021 |  proactiveinvestors.com
Why There's Still Need for Rapid Accessible Pathogen Testing, During and After the Crisis
January 13, 2021 |  marketwatch.com
LexaGene starts studies required by the FDA for Emergency Use...LexaGene starts studies required by the FDA for Emergency Use...
January 1, 2021 |  proactiveinvestors.com
LexaGene Holdings set to deploy its MiQLab Systems at two veterinary hospitals in US
December 19, 2020 |  proactiveinvestors.com
LexaGene places MiQLab system in microbiology lab at University of Pennsylvania's School of Veterinary Medicine
November 20, 2020 |  proactiveinvestors.com
LexaGene Places MiQLab System at the University of Pennsylvania’s School of Veterinary Medicine
November 18, 2020 |  markets.businessinsider.com
LexaGene receives purchase order for a MiQLab system from a multinational biotechnology company
November 16, 2020 |  proactiveinvestors.com
See More Headlines

MarketRank™

Overall MarketRank™

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$0.75
-0.01 (-1.32 %)
(As of 04/9/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LXG News and Ratings via Email

Sign-up to receive the latest news and ratings for LXG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LexaGene (CVE:LXG) Frequently Asked Questions

What stocks does MarketBeat like better than LexaGene?

Wall Street analysts have given LexaGene a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LexaGene wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has LexaGene's stock been impacted by Coronavirus (COVID-19)?

LexaGene's stock was trading at C$0.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LXG shares have increased by 2.7% and is now trading at C$0.75.
View which stocks have been most impacted by COVID-19.

Who are LexaGene's key executives?

LexaGene's management team includes the following people:
  • Dr. John F. Regan, Founder, Chairman & CEO
  • Mr. Jeffrey Mitchell, CFO, Treasurer & Corp. Sec.
  • Mr. Steven Armstrong, Chief Operating Officer
  • Mr. Allan John Fabbro, VP of Corp. Devel. (Age 64)
  • Nicole Ridgedale, Director of Corp. Marketing
  • Jay Adelaar, VP of Capital Markets

Who are some of LexaGene's key competitors?

Some companies that are related to LexaGene include Lucira Health (LHDX), Akumin (AKU), Akumin (AKU), Inotiv (NOTV), Oncimmune (ONC), Yourgene Health (YGEN), Abingdon Health (ABDX), Relay Medical (RYMDF), SQI Diagnostics (SQD), Global WholeHealth Partners (GWHP), genedrive (GDR), Cambridge Cognition (COG), Sernova (SVA), GeneNews (GEN) and Deepmatter Group (DMTR).
View all of LXG's competitors.

What other stocks do shareholders of LexaGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LexaGene investors own include Jaguar Mining (JAG), Northern Superior Resources (SUP), Vaccinex (VCNX), Gevo (GEVO), HIVE Blockchain Technologies (HIVE), (CVLB), EQT (EQT), Freehold Royalties (FRU), GFG Resources (GFG) and IAMGOLD (IMG).

What is LexaGene's stock symbol?

LexaGene trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LXG."

How do I buy shares of LexaGene?

Shares of LXG and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is LexaGene's stock price today?

One share of LXG stock can currently be purchased for approximately C$0.75.

How much money does LexaGene make?

LexaGene has a market capitalization of C$85.77 million.

How many employees does LexaGene have?

LexaGene employs 36 workers across the globe.

What is LexaGene's official website?

The official website for LexaGene is www.lexagene.com.

How can I contact LexaGene?

The company can be reached via phone at 800-215-1824.


This page was last updated on 4/10/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.